Skip to main content

Table 1 P values calculated from independent samples t tests (two-tailed, equal variance not assumed) for tumor volume, tumor FAZA uptake, and tumor hypoxic fraction parameters at various study time points.

From: Longitudinal tumor hypoxia imaging with [18F]FAZA-PET provides early prediction of nanoliposomal irinotecan (nal-IRI) treatment activity

  1. Statistically significant difference in tumor FAZA uptake (expressed both in terms of %ID/g and tumor hypoxic fraction) is found on day 7 post-treatment initiation between the nal-IRI (10 mg/kg) and the other two treatment groups. Statistically significant difference in tumor volume, for the same groups, is seen on day 10 and 16. A total of 10 tumors were included in the analysis for each group on days 4 through 16. On day 21, the number of tumors per group was 4, 6, and 8 for irinotecan, nal-IRI (10 mg/kg) and nal-IRI (5 mg/kg), respectively